BioCryst Pharma (BCRX) Misses Q2 EPS by 4c

BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.23), $0.04 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.32 million.

Based upon current trends, assumptions, and development plans, BioCryst continues to expect its 2014 net operating cash use to be in the range of $35 to $43 million, and its operating expenses to be in the range of $48 to $59 million. Our operating expense range excludes equity-based compensation expense due to the difficulty in projecting this expense, as it is impacted by the volatility and price of the Company's stock, as well as by the vesting of the Company's outstanding performance-based stock options.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Sandisk targets mid-to-high teens revenue growth through FY2030
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance